NCT04651153

A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD)

A Multicenter, Participant-Blind, Investigator-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of UCB7853 in Healthy Male Study Participants and Multiple Ascending Doses in Patients With Parkinson's Disease

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 62 (actual)
• Sponsor: UCB Biopharma SRL · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

The primary purpose of the study is to evaluate the safety and tolerability of single ascending doses of UCB7853 in healthy male study participants and to evaluate the safety and tolerability of multiple ascending doses of UCB7853 administered in study participants with Parkinson's Disease (PD)

Conditions

• Parkinson's Disease

Interventions

Type	Name	Description
DRUG	UCB7853	Subjects will receive UCB7853 at pre-specified time-points.
OTHER	Placebo	Subjects will receive Placebo at pre-specified time-points.

Timeline

• Start date: 2020-12-14
• Primary completion: 2023-07-20
• Completion: 2023-07-20
• First posted: 2020-12-03
• Last updated: 2024-07-08

Locations

2 sites across 2 countries: Netherlands, United Kingdom